Transgene and BioInvent Receive IND Approval from the US FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors

Transgene and BioInvent International AB announce that their Investigational New Drug application for BT-001 has been granted by the US FDA. This IND will allow patients in the US to be enrolled into the ongoing Phase I/IIa clinical trial of this novel oncolytic virus BT-001.